<html><body><pre>
[Congressional Bills 113th Congress]
[From the U.S. Government Printing Office]
[H.R. 413 Introduced in House (IH)]

113th CONGRESS
  1st Session
                                H. R. 413

To eliminate the 2-year delay in including oral-only ESRD-related drugs 
  in the Medicare ESRD prospective payment system, as provided under 
     section 632(b)(1) of the American Taxpayer Relief Act of 2012.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            January 23, 2013

Mr. Welch (for himself, Mr. Hanna, Mr. Cooper, and Mr. Braley of Iowa) 
 introduced the following bill; which was referred to the Committee on 
   Energy and Commerce, and in addition to the Committee on Ways and 
 Means, for a period to be subsequently determined by the Speaker, in 
   each case for consideration of such provisions as fall within the 
                jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL


 
To eliminate the 2-year delay in including oral-only ESRD-related drugs 
  in the Medicare ESRD prospective payment system, as provided under 
     section 632(b)(1) of the American Taxpayer Relief Act of 2012.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ELIMINATING THE 2-YEAR DELAY IN IMPLEMENTATION OF ORAL-ONLY 
              ESRD-RELATED DRUGS IN THE MEDICARE ESRD PROSPECTIVE 
              PAYMENT SYSTEM.

    Section 632(b) of the American Taxpayer Relief Act of 2012 (Public 
Law 112-240) is amended by striking all that precedes ``With respect to 
the implementation'' and inserting the following::
    ``(b) Monitoring of Implementation of Oral-Only ESRD-Related Drugs 
in the ESRD Prospective Payment System.--With respect to the 
implementation''.
                                 &lt;all&gt;
</pre></body></html>
